CASPR2自身免疫抗体诱导人类大脑器官中的神经元过活.
Ana Rafaela Oliveira1,2,3, Giuseppe Cammarata1,4, Catarina Seabra1,3
1CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Journal of neurochemistry
|February 23, 2026
概括
针对接触因相关蛋白类2 (CASPR2) 的母体自身抗体可能会破坏胎儿大脑发育. 暴露于人类神经器官中的抗CASPR2抗体诱导了神经元过敏,这是神经发育障碍的标志.
科学领域:
- 神经科学是一个神经科学.
- 发育生物学 发展生物学
- 免疫学 免疫学 免疫学
背景情况:
- 大脑反应性抗体的妊娠转移对神经发育障碍构成风险.
- 接触因相关蛋白类2 (CASPR2) 是孕产妇自身抗体的标,与胎儿神经发育有关.
- 对于CASPR2抗体对人类大脑发育的确切影响尚不清楚.
研究的目的:
- 研究CASPR2自身抗体对人类大脑发育的神经生理影响.
- 阐明CASPR2抗体诱导的神经发育变化的潜在机制.
主要方法:
- 在具有抗CASPR2抗体的介质中培养了未指导的人类神经器官6个月.
- 在急性有机体片中使用全细胞补丁和成像进行神经生理学表征.
主要成果:
- 暴露于CASPR2抗体显著增加了自发突触活动.
- 观察到动作潜能发射的最大频率提高和自发网络活动.
- 动力电位波形的变化表明CASPR2在调节电压关闭通道中的作用.
结论:
- 在人类神经器官中,CASPR2自身抗体会诱导神经元过激发性.
- 这种过度兴奋现象类型反映了神经发育障碍模型中的发现.
- 在发育过程中,CASPR2自身抗体可能在驱动神经元过激动性方面发挥病理作用.
相关概念视频
GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Postsynaptic Potential (PSP)
Postsynaptic potential (PSP) refers to a change in the electrical potential of a neuron when neurotransmitters released by presynaptic neurons bind to postsynaptic receptors. This potential can either be excitatory, leading to depolarization and ultimately action potential generation, or inhibitory, leading to hyperpolarization and suppression of the postsynaptic neuron.
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


